Role of endothelin in modulation of heart rate variability in patients with decompensated heart failure

D Aronson1, M A Mittleman, A J Burger

  • 1Division of Cardiology, RAMBAM Medical Center, Haifa, Israel.

Insights

Elevated endothelin-1 (ET-1) levels are linked to reduced heart rate variability (HRV) in congestive heart failure (CHF) patients. This suggests ET-1 contributes to autonomic dysfunction and that HRV may indicate neurohormonal activation in CHF.

Area of Science:

  • Cardiology
  • Autonomic Neuroscience
  • Biomedical Research

Background:

  • Endothelin-1 (ET-1) is known to influence sympathetic nervous system activity.
  • The role of elevated ET-1 in autonomic dysfunction associated with congestive heart failure (CHF) remains unclear.
  • Heart rate variability (HRV) is a key indicator of autonomic function, often depressed in CHF.

Purpose of the Study:

  • To investigate whether increased ET-1 levels contribute to the diminished HRV observed in patients with CHF.
  • To explore the relationship between ET-1 levels and various HRV metrics in a CHF cohort.

Main Methods:

  • Sixty-four patients hospitalized for decompensated CHF underwent 24-hour Holter monitoring for HRV analysis.
  • Plasma levels of ET-1, renin activity (PRA), aldosterone, and norepinephrine were measured.
  • Time-domain (e.g., SDNN, SDANN5) and frequency-domain (e.g., Total Power, ULF, HF, LF) HRV indices were calculated.

Main Results:

  • ET-1 showed significant negative correlations with overall HRV indices: SDNN (r=-0.38, P=0.002), SDANN5 (r=-0.48, P<0.0001), and Total Power (r=-0.32, P=0.01).
  • A strong negative association persisted between ET-1 and SDNN, SDANN5, and ultralow frequency (ULF) power after adjusting for clinical factors and other neurohormones (P=0.027, P=0.002, P=0.017, respectively).
  • No significant correlations were found between ET-1 and HRV indices specifically reflecting parasympathetic or sympathovagal modulation.

Conclusions:

  • Elevated ET-1 levels appear to play a significant role in the autonomic dysfunction characteristic of CHF.
  • The strong correlation between ET-1 and prognostically important HRV measures suggests HRV indices may serve as valuable markers of neurohormonal activation in CHF.
  • HRV's discriminatory power for risk stratification in CHF may be partly explained by its association with neurohormonal status, particularly ET-1.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Regulation of Heart Rates01:31

Regulation of Heart Rates

The regulation of heart rate is a complex process controlled by the autonomic nervous system (ANS), hormonal influences, and intrinsic cardiac mechanisms. The ANS has two main components: the sympathetic nervous system (SNS) and the parasympathetic nervous system (PNS).
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...